Fig. 2: In vivo effect of targeting CCL2 or CCR2 in combination with anti-PD-1 immunotherapy. | Communications Biology

Fig. 2: In vivo effect of targeting CCL2 or CCR2 in combination with anti-PD-1 immunotherapy.

From: Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy

Fig. 2: In vivo effect of targeting CCL2 or CCR2 in combination with anti-PD-1 immunotherapy.

a Subcutaneous tumor growth in syngeneic mice injected with NA13 cells (n = 6 biologically independent mice per group). Data representative of two independent experiments. Statistical significance was determined by two-way ANOVA. Arrows indicate dates in which anti-PD-1 treatment was given. Mean ± SD. b Individual tumor volumes as a function of time. Each line represents a single mouse (n = 10 or 11 biologically independent mice per group). c Waterfall plot showing change in NA13 tumor volume on endpoint day 30 post tumor injection compared to baseline prior to treatment with and without CCR2 antagonist RS504393 and/or anti-PD-1 treatment. Starting on day 14, mice were treated daily with CCR2 antagonist RS503393, and every three days with anti-PD-1.

Back to article page